title: Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox).
abstract: BACKGROUND
  Like endothelial and smooth muscle cells, vascular adventitial fibroblasts contain a substantial NAD(P)H oxidase superoxide anion (O2-)-generating system activated by angiotensin II (Ang II). Based on the ability of nitric oxide (NO*) to diffuse rapidly through tissue and the fast reaction rate of NO* and O2-, we postulated that the interaction between NO. and adventitial NAD(P)H oxidase-derived O2- contributes to impairment of endothelium-dependent relaxation (EDR).
  
  
  RESULTS
  C57Bl/6 mouse abdominal aortas were simultaneously perfused intraluminally and suffused adventitially with physiological buffer at 37 degrees C. After constricting the vessels with phenylephrine, an acetylcholine dose-response curve was obtained while monitoring changes in diameter by videomicroscopy. Endogenous O2- was increased by treating the adventitial side of the aortas with Ang II (10 pmol/L), leading to impairment of EDR. EDR impairment was reversed by adventitial suffusion of superoxide dismutase (SOD) of aortas from wild-type mice. Ang II-treated aortas from gp91(phox-/-) mice, which lack significant adventitial O2-, exhibited greater EDR and were not affected by SOD. Adventitially suffused SOD failed to penetrate the media, indicating that the effects of SOD were localized to the adventitia. Adventitial application of the O2--generating system xanthine/xanthine oxidase or the potent NO scavenger oxyhemoglobin impaired EDR.
  
  
  CONCLUSIONS
  O2- derived from adventitial gp91(phox)-based NAD(P)H oxidase contributes to impairment of the action of endothelium-derived NO.
authors.affiliation: Hypertension & Vascular Research Division, Henry Ford Hospital, Detroit, Mich 48202-2689, USA.
authors.forename: Federico E
authors.initials: FE
authors.lastname: Rey
authors.forename: Xiao-Chun
authors.initials: XC
authors.lastname: Li
authors.forename: Oscar A
authors.initials: OA
authors.lastname: Carretero
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Garvin
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Pagano
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D006861:Hydrogen Peroxide / Q000494:pharmacology; D066298:In Vitro Techniques; D008562:Membrane Glycoproteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases; D009569:Nitric Oxide / Q000378:metabolism; D016877:Oxidants / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology; D010108:Oxyhemoglobins / Q000494:pharmacology; D010477:Perfusion; D013482:Superoxide Dismutase / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism*; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*; D014665:Vasodilator Agents / Q000494:pharmacology; D019820:Xanthine / Q000378:metabolism / Q000494:pharmacology; D014969:Xanthine Oxidase / Q000378:metabolism / Q000494:pharmacology
chemical_list: D008562:Membrane Glycoproteins; D016877:Oxidants; D010108:Oxyhemoglobins; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D013481:Superoxides; D000804:Angiotensin II; D019820:Xanthine; D009569:Nitric Oxide; D006861:Hydrogen Peroxide; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase; D009247:NADH, NADPH Oxidoreductases; C056558:CYBB protein, human; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases; D010100:Oxygen